Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Recruiting

Phase 1

BBI-355Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Sponsor:

Boundless Bio

Code:

NCT05827614

Conditions

Triple Negative Breast Cancer (TNBC)

High Grade Serous Ovarian Carcinoma

High Grade Endometrial Carcinoma

Anogenital Cancer

Head and Neck (HNSCC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BBI-355

Erlotinib

Futibatinib

BBI-825

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-17. This information was provided to ClinicalTrials.gov by Boundless Bio on 2025-09-22.